Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:BLPH NYSEAMERICAN:OGEN NASDAQ:PCSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$23.32$17.82$8.61▼$23.36$150.70M0.44459,444 shs175,627 shsBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shsN/AOGENOragenics$0.57-2.9%$0.67$0.50▼$9.60$2.65M1.2652,786 shs57,952 shsPCSAHeatwurx$2.75-7.1%$2.78$1.76▼$19.64$8.14M1.0161,796 shs52,807 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio0.00%+3.64%+29.48%+88.37%+133.50%BLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%0.00%OGENOragenics0.00%-1.44%-17.71%-10.37%-90.19%PCSAHeatwurx0.00%+8.42%-4.52%+33.33%-49.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$23.32$17.82$8.61▼$23.36$150.70M0.44459,444 shs175,627 shsBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shsN/AOGENOragenics$0.57-2.9%$0.67$0.50▼$9.60$2.65M1.2652,786 shs57,952 shsPCSAHeatwurx$2.75-7.1%$2.78$1.76▼$19.64$8.14M1.0161,796 shs52,807 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio0.00%+3.64%+29.48%+88.37%+133.50%BLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%0.00%OGENOragenics0.00%-1.44%-17.71%-10.37%-90.19%PCSAHeatwurx0.00%+8.42%-4.52%+33.33%-49.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 1.80Reduce$22.65-2.87% DownsideBLPHBellerophon Therapeutics 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/APCSAHeatwurx 2.00Hold$25.00809.09% UpsideCurrent Analyst Ratings BreakdownLatest OGEN, BLPH, PCSA, and ASRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$21.80 ➝ $23.505/5/2026ASRTAssertio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $21.804/21/2026PCSAHeatwurx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ASRTAssertio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026ASRTAssertio Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/9/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$45.00 ➝ $18.004/9/2026ASRTAssertio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$35.00 ➝ $18.003/6/2026ASRTAssertio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$118.71M1.27$0.02 per share1,426.28$14.63 per share1.59BLPHBellerophon Therapeutics$5.64M0.03N/AN/A$0.27 per share0.04OGENOragenics$40K64.39N/AN/A$1.94 per share0.29PCSAHeatwurxN/AN/AN/AN/A$2.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$30.38M-$5.69N/A21.01N/A-34.94%-38.72%-13.32%7/30/2026 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/AN/AN/AN/AN/AN/AN/AOGENOragenics-$9.84M-$21.42N/AN/AN/AN/A-177.32%-121.29%N/APCSAHeatwurx-$13.56M-$8.00N/AN/AN/AN/A-281.31%-200.80%8/6/2026 (Estimated)Latest OGEN, BLPH, PCSA, and ASRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026ASRTAssertio-$2.1025-$2.93-$0.8275-$2.93$8.97 million$9.93 million5/8/2026Q1 2026OGENOragenicsN/A-$0.51N/A-$0.51N/AN/A3/16/2026Q4 2025ASRTAssertio-$3.05-$1.86+$1.19-$1.86$6.20 million$13.54 million3/16/2026Q4 2025OGENOragenicsN/A$0.60N/A$0.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.521.821.57BLPHBellerophon TherapeuticsN/AN/AN/AOGENOragenicsN/A5.735.73PCSAHeatwurxN/A0.980.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%BLPHBellerophon Therapeutics10.61%OGENOragenics18.71%PCSAHeatwurx91.93%Insider OwnershipCompanyInsider OwnershipASRTAssertio5.70%BLPHBellerophon Therapeutics5.20%OGENOragenics10.10%PCSAHeatwurx2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio206.46 million6.09 millionOptionableBLPHBellerophon Therapeutics2012.23 million11.60 millionNo DataOGENOragenics54.51 million4.06 millionN/APCSAHeatwurx202.75 million2.68 millionNot OptionableOGEN, BLPH, PCSA, and ASRT HeadlinesRecent News About These CompaniesProcessa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare ConferenceJanuary 12, 2026 | globenewswire.comProcessa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer StudyJanuary 5, 2026 | globenewswire.comPCSA Stock Soars on Upbeat Clinical Update From Breast Cancer StudyDecember 18, 2025 | zacks.comProcessa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast CancerDecember 17, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025November 5, 2025 | globenewswire.comProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury StrategiesAugust 7, 2025 | globenewswire.comProcessa Pharmaceuticals Provides Portfolio and Business UpdateJuly 1, 2025 | globenewswire.comProcessa Pares Gains on Equity Offer NewsJune 17, 2025 | marketwatch.comProcessa Pharmaceuticals Announces Pricing of $7 Million Public OfferingJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals Enters Exclusive Licensing Agreement with Intact Therapeutics for PCS12852, Potential Treatment for GastroparesisJune 17, 2025 | quiverquant.comQProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug CandidateJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International ConventionJune 15, 2025 | nasdaq.comProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025June 13, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual MeetingMay 30, 2025 | globenewswire.comProcessa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | markets.businessinsider.comProcessa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 18, 2025 | globenewswire.comProcessa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | insidermonkey.comProcessa Pharmaceuticals faces Nasdaq delisting risk over share priceFebruary 10, 2025 | msn.comFavourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired StockFebruary 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026Aeluma’s Market Is Laser-Focused on Fresh Highs—Here’s WhyBy Thomas Hughes | April 20, 2026Plug Power Flips The Switch On ProfitabilityBy Jeffrey Neal Johnson | May 13, 2026Aeluma's Post-Earnings Dip Creates a Buying OpportunityBy Thomas Hughes | May 15, 2026OGEN, BLPH, PCSA, and ASRT Company DescriptionsAssertio NASDAQ:ASRT$23.32 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$23.35 +0.03 (+0.12%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Bellerophon Therapeutics NASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Oragenics NYSEAMERICAN:OGEN$0.57 -0.02 (-2.94%) Closing price 04:10 PM EasternExtended Trading$0.58 +0.01 (+1.91%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Heatwurx NASDAQ:PCSA$2.75 -0.21 (-7.09%) Closing price 04:00 PM EasternExtended Trading$2.88 +0.13 (+4.69%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
